Page 75 - 51 the significance--29.2_opt

24. Scott R, Wu M, Sanchez M, Stein P. Efficacy and tolerability of the dipeptidyl
peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2
diabetes. International journal of clinical practice 2007;61(1):171-80.
25. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety
of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with
type 2 diabetes mellitus. Diabetologia 2006;49(11):2564-71.
26. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE.
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic
control in patients with type 2 diabetes. Diabetes care 2006;29(12):2632-7.
27. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the
dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide,
in patients with type 2 diabetes inadequately controlled on metformin alone:
a randomized, double-blind, non-inferiority trial. Diabetes, obesity & metabolism
2007;9(2):194-205.
28. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added
to ongoing metformin therapy in patients with type 2 diabetes. Diabetes, obesity &
metabolism 2008;10(10):959-69.
29. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the
dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in
patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes
care 2006;29(12):2638-43.
30. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect
of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor,
and metformin on glycemic control in patients with type 2 diabetes. Diabetes care
2007;30(8):1979-87.
31. Qi D, Teng R, Jiang M, et aI. Two-year treatment with sitagliptin and initial combination
therapy of sitaglitpin and metformin provides substantial and durable glycaemic
control in patients with type 2 diabetes. Diabetologia 2008;519(Suppl1):S36.
32. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl
peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients
with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-
controlled, parallel-group study. Clinical therapeutics 2006;28(10):1556-68.
33. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of
the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes
mellitus inadequately controlled on glimepiride alone or on glimepiride and met-
formin. Diabetes, obesity & metabolism 2007;9(5):733-45.
34. Arjona Ferreira J, Dobs A, Goldstein B. Triple combination therapy with sitagliptin,
metformin and rosiglitazone improves glycaemic control in patients with type 2
diabetes. Diabetologia 2008;51(Suppl 1):S365.
35. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition
of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces
glucagon levels in type 2 diabetes. The Journal of clinical endocrinology and
metabolism 2004;89(5):2078-84.
36. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy
with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2
diabetes. Hormone and metabolic research = Hormon- und Stoffwechselforschung
= Hormones et metabolisme 2006;38(6):423-8.
37. Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin
monotherapy in drug-naive patients with type 2 diabetes. Diabetes research and
clinical practice 2007;76(1):132-8.
38. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with
type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled,
multiple-dose study. Hormone and metabolic research = Hormon- und Stoffwech-
selforschung = Hormones et metabolisme 2007;39(3):218-23.
39. Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A. Comparison of vildagliptin
and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week,
double-blind, randomized trial. Diabetes care 2007;30(2):217-23.
40. Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Wang Y, et al. Evidence
that vildagliptin attenuates deterioration of glycaemic control during 2-year treat-
ment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes, obesity
& metabolism 2008;10(11):1114-24.
41. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on
glucose control over 24 weeks in patients with type 2 diabetes inadequately con-
trolled with metformin. Diabetes care 2007;30(4):890-5.

75